Author: Richter, Anja ; Bertzbach, Luca D ; Dietert, Kristina ; Hoffmann, Julius ; Endres, Matthias ; Wilson, Ian A ; Homeyer, Marie A ; Jeworowski, Lara Maria ; Schwarz, Tatjana ; Sander, Leif E ; Skriner, Karl ; van Hoof, Scott ; Gruber, Achim D ; Suttorp, Norbert ; Corman, Victor Max ; Liu, Hejun ; Stöffler, Laura ; Yuan, Meng ; Barthel, Paula Charlotte ; Kurth, Florian ; Li, Lucie Y ; Hocke, Andreas C ; Schmitz, Dietmar ; von Wardenburg, Niels ; Abdelgawad, Azza ; Schmidt, Marie Luisa ; Wu, Nicholas C ; Trimpert, Jakob ; Reincke, S Momsen ; Vladimirova, Daria ; Witzenrath, Martin ; Prüss, Harald ; Osterrieder, Nikolaus ; Kreye, Jakob ; Müller, Marcel Alexander ; Hippenstiel, Stefan ; Drosten, Christian ; Höltje, Markus ; Sánchez-Sendin, Elisa ; Zhu, Xueyong ; Kornau, Hans-Christian ; Wendisch, Daniel ; Franke, Christiana ; Lee, Chang-Chun D

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC₅₀ value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

Signal Transduction and Targeted TherapyQ1 · MEDICINE

‘nAb’ the self-reactive activity in the COVID-19 combat

Q1 · MEDICINE

ArticleOA

Author: Narasimhan, Madhusudhanan ; Muthukumar, Alagarraju ; Mahimainathan, Lenin

In this article studies about a 'nAb' the self-reactive activity in the COVID-19 combat.It is imperative to consider the aspects linked to immunogenicity and response, viz., the dose, frequency, route, and time of administration.A prophylactic and therapeutic application of CV07-209, a COVID-19 patient-derived ns-nAb conferred protection against SARS-CoV-2-induced bronchopulmonary pathol. in a hamster model.

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

Author: Hippenstiel, Stefan ; Wilson, Ian A ; Zhu, Xueyong ; Yuan, Meng ; Sander, Leif E ; Schwarz, Tatjana ; Sánchez-Sendin, Elisa ; Homeyer, Marie A ; Endres, Matthias ; Max Corman, Victor ; von Wardenburg, Niels ; Hoffmann, Julius ; Skriner, Karl ; Trimpert, Jakob ; Wendisch, Daniel ; Witzenrath, Martin ; Barthel, Paula Charlotte ; Stöffler, Laura ; Hocke, Andreas C ; Osterrieder, Nikolaus ; Richter, Anja ; Franke, Christiana ; Suttorp, Norbert ; Abdelgawad, Azza ; Vladimirova, Daria ; Drosten, Christian ; Schmitz, Dietmar ; van Hoof, Scott ; Li, Lucie Y ; Höltje, Markus ; Reincke, S Momsen ; Jeworowski, Lara Maria ; Lee, Chang-Chun D ; Dietert, Kristina ; Wu, Nicholas C ; Müller, Marcel Alexander ; Kreye, Jakob ; Schmidt, Marie Luisa ; Liu, Hejun ; Gruber, Achim D ; Prüss, Harald ; Kornau, Hans-Christian ; Kurth, Florian ; Bertzbach, Luca D

ABSTRACTThe emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

100 Deals associated with CV07-209

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	DE	Charité - Universitätsmedizin Berlin	-
COVID-19	Preclinical	DE	Miltenyi GmbH	-
COVID-19	Preclinical	DE	German Center for Neurodegenerative Diseases	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CV07-209

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation